| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC2101 | Erlotinib free base Featured | Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
|
| DC3139 | Erlotinib hydrochloride Featured | Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
|
| DC10380 | Evobrutinib Featured | Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174. |
|
| DC10128 | FGF401( Roblitinib) Featured | FGF401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. |
|
| DC9933 | FGFR4-IN-1 | FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM. |
|
| DC8330 | FIIN-2 Featured | FIIN-2 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor. |
|
| DC9642 | FIIN-3 Featured | FIIN-3 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor. |
|
| DC8164 | Gilteritinib(ASP2215) Featured | FLT3/AXL inhibitor |
|
| DC11780 | FLT3-IN-5e | FLT3-IN-5e is a nove potent, selective FLT3 inhibitor with Kd of 3.6 nM, IC50 of <6 nM. |
|
| DC7937 | LFM-A13 Featured | FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC₅₀’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK). |
|
| DC8174 | Pexmetinib(ARRY-614) Featured | Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia. |
|
| DC7342 | Foretinib(XL880) Featured | Foretinib (GSK1363089; XL880; EXEL-2880; GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. |
|
| DC7902 | Fruquintinib (HMPL-013) Featured | Fruquintinib (HMPL-013) is a novel small molecule compound that selectively inhibits vascular endothelial growth factor receptors (VEGFRs). |
|
| DC11776 | G-744 | G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM. |
|
| DC7792 | G-749 Featured | G-749 is an inhibitor of Fms-like tyrosine receptor kinase 3 (FLT3) with IC50 values ranging from 2.1 to 38.1 nM for wild-type and mutant (constitutively active) FLT3s in Ba/F3 cells expressing recombinant receptors. |
|
| DC9942 | GDC-0853(RG7845) Featured | GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. |
|
| DC2103 | Gefitinib (ZD1839) Featured | Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
|
| DC11543 | Glumetinib Featured | Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM. |
|
| DC1062 | GNF-2 Featured | GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, inhibiting the proliferation of the Bcr-Abl-expressing cells with IC50 of 138 nM. |
|
| DC9285 | GNF-7 Featured | GNF-7 is a potent type-II kinase Bcr-Abl inhibitor with IC50 of <5 nM, 61 nM, 122 nM, 136 nM, and 133 nM for M351T, T315I, E255 V, G250E, and c-Abl, respectively. |
|
| DC2069 | IGF-1R inhibitor GS1904529A | GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM, respectively. |
|
| DC8331 | GSK2256098 Featured | GSK2256098 is small molecule FAK kinase inhibitor. |
|
| DC10936 | GSK3179106 Featured | GSK3179106 (GSK-3179106, GSK 3179106) is a potent, selective, first-in-class and gut-restricted with IC50 of 0.4 and 11 nM in the biochemical assay and cellular assay respectively. |
|
| DC7145 | GW441756 Featured | GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM; little activity to c-Raf1 and CDK2. |
|
| DC1018 | GW-2580 (GW2580) Featured | GW2580 is a selective inhibitor of human c-FMS with IC50 of 30 nM. |
|
| DC10033 | H3B-6527 Featured | H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. |
|
| DC10596 | Lavendustin C (HDBA) Featured | HDBA, a derivative of a Streptomyces griseolavendus butyl acetate extract, is a potent inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase with an IC50 value of 0.012 µM. |
|
| DC11366 | HKI 357 | HKI 357 is an irreversible dual inhibitor of the EGF receptor tyrosine kinases EGFR and HER2 (IC50s = 34 and 33 nM, respectively). |
|
| DC8819 | Olmutinib (HM61713; BI-1482694) Featured | HM-61713 (BI-1482694) is an orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. |
|
| DC12259 | HS-10296 hydrochloride | HS-10296 hydrochloride is an orally available and third-Generation inhibitor of epidermal growth factor receptor (EGFR)-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR. |
|
